SENISCA is seeking to expand its Scientific Advisory Board [SAB] with 3 new members. SAB members will be expected to attend quarterly meetings to support SENISCA’s Chief Scientific Officer and Executive team across each R&D division of the business. Meetings will be either in-person at SENISCA’s Exeter UK-based R&D lab facilities or on-line via Zoom.

We are looking for either academic, biotech or pharmaceutical sector individuals with the following experience. Our aim is that at least 2 of the 3 candidates will have an oligonucleotide drug development background:

• A track record of accomplishments in leading drug discovery teams from target identification through delivery of clinical candidates and establishing clinical translational strategy.
• Expertise (scientifically or commercially) in an area of oligonucleotide therapeutics, or within any of the broad range of age-related disease(s) targeted by SENISCA’s platform technology.
• Expertise in oligonucleotide synthesis and chemical modification.
• Expertise in oligonucleotide cell delivery technology.

Please send CVs and initial enquiries to: HR@senisca.com addressed to Anna Bennett (SENISCA’s Business Co-ordinator), within the initial application window of the 15th February to 15th of March 2022.